PwC’s IPO Lead On A Selective Market, AI Valuations And The Outlook For 2027

Startups & Funding

US IPO Market Ran at Just Under 90 Deals as Momentum Stalls

Just under 90 U.S. IPOs have priced this year versus a 125-175 healthy norm, PwC's Bellin says, with valuation disputes pausing issuers and AI spend under scrutiny ahead of 2027.

By
Grace Kim
Filed
Channel
Startups & Funding
Read
4 min read

The U.S. has recorded just under 90 traditional IPOs this year, against a benchmark of 125 to 175 for a healthy market, according to Mike Bellin, partner and U.S. IPO services leader at PricewaterhouseCoopers. The shortfall reflects a market that slowed sharply in September and October after three strong quarters, not one that has closed.

Bellin laid out his assessment in an interview with Crunchbase News, covering the slowdown, investor scrutiny of AI issuers, biotech's revival, SPACs and the outlook for 2027.

How healthy is the IPO market?

A good U.S. IPO year runs 125 to 175 traditional offerings, Bellin said. Year to date, the count sits just south of 90. The breadth of issuance has nonetheless been healthy: industrial products, technology, consumer markets, energy, utilities and some financial services have all returned to market.

"Is the market in trouble? I would say no," Bellin said. "It's very selective. It's not shut. Quality issuers with readiness, the right story, the right metrics can still get their deals done."

What caused the slowdown?

Bellin pointed first to the macro environment. Rates, inflation and geopolitical concerns created uncertainty. Valuation was the second driver. Some issuers asked for aggressive valuations, and the market judged them rich given the uncertainty. Many issuers chose to pause and wait for another window.

What do public investors want?

Two items dominate. The first is durable revenue — revenue backed by strong, diverse customers, a growing base and significant backlog of demand. The second is leverage. Companies carrying significant debt face two questions in a rising-rate environment: can they take on new leverage profitably, and can they refinance existing debt? A reasonable leverage ratio, or a clear equity story on return on debt capital, makes a significant difference, Bellin said.

Scale matters too. Large companies, by revenue or assets depending on sector, can almost dictate their listing window. Smaller and midmarket issuers outside life sciences have been challenged.

Will AI enthusiasm survive public scrutiny?

"Investors aren't skeptical of AI; they're skeptical of spend without visibility," Bellin said. Visibility means clear paths to future earnings and durable revenue. The market is separating AI companies with visible demand and backlog from those with only a narrative.

Profitability is the other test. Bellin said it may be measured as GAAP income, EBITDA, cash flow, free cash flow or levered free cash flow. "We haven't seen a period like this of development, of growth, ever before," he said, adding that the market will discern which companies are public-company worthy.

What does uneven post-IPO trading signal?

It signals selectivity. The market has produced big winners alongside companies that traded below expectations. Aggressive pricing risks a post-IPO decline, which damages the metrics. Bellin said companies now come to market better prepared than ever, given the volatility.

Why is biotech resurging?

M&A is the engine, Bellin said. Large health companies losing patents on profitable drugs are hunting the next generation of development, and many biotechs are purchased by large pharma before reaching public markets. That competition creates a trade-off for each company: an IPO with upside versus an M&A exit with day-one certainty. Biotech assets have traded well after listing, building a flywheel effect the rest of the market has lacked in recent months.

Why are SPACs back in conversation?

Volatility has revived SPAC discussions. A SPAC sets valuation certainty on day one, so a company knows the potential cash it may receive, though redemptions can reduce it. Serial SPAC issuers understand the product and can judge whether a target will hit the milestones in the offering document. Bellin called today's SPAC market healthier and more mature than in the past, while noting that many SPACs are still searching for targets amid a large inventory.

What should the market expect in 2027?

Hundreds of companies are in the pipeline and ready to go when conditions allow. Bellin expects private equity, active in 2026, to stay active in 2027, and he cites buy-side demand and available capital for the right companies, plus strength in the AI ecosystem, energy, consumer and industrial products. "I think we're in for a strong year," he said, "but it will remain selective."

Source: news.crunchbase.com

Share this article:

More from Grace Kim

Grace Kim

Show full bio

Market editor covering people, launches and day-to-day practice in Semiconductors, chip manufacturing, hardware, AI compute at Chip Dispatch.

1,053 articles

Related articles

« Previous article